Crystalline dimethyl tryptamine analogues

Abstract

The disclosure relates to N-methyl-N-allyl-tryptamine (MALT) hydrofumarate, crystalline MALT hydrofumarate, N—N-dibutyl-tryptamine (DBT) iodide, crystalline DBT iodide, crystalline N-ethyl-N-propyl-tryptamine (EPT) hydrofumarate, and crystalline N—N-diisopropyl-tryptamine (DiPT) hydrofumarate, compositions containing them, and the methods of treatment using them.

The claimed invention is: 
     
         1 . A DMT analogue compound selected from the group consisting of:
 N-methyl-N-allyl-tryptamine (MALT) hydrofumarate;   N—N-dibutyl-tryptamine (DBT) iodide;   crystalline MALT hydrofumarate;   crystalline DBT iodide;   crystalline N-ethyl-N-propyl-tryptamine (EPT) hydrofumarate; and   crystalline N—N-diisopropyl-tryptamine (DiPT) hydrofumarate.   
     
     
         2 . A composition comprising a DMT analogue compound according to  claim 1  and an excipient. 
     
     
         3 . A composition comprising a DMT analogue compound according to  claim 1  and a second component selected from (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) one or two purified cannabinoids, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a purified erinacine, and (h) a purified hericenone. 
     
     
         4 . A composition comprising:
 a DMT analogue compound selected from the group consisting of: N-methyl-N-allyl-tryptamine (MALT) hydrofumarate; N—N-dibutyl-tryptamine (DBT) iodide; N-ethyl-N-propyl-tryptamine (EPT) hydrofumarate; and N—N-diisopropyl-tryptamine (DiPT) hydrofumarate; and   a second component selected from (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) one or two purified cannabinoids, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a purified erinacine, and (h) a purified hericenone.   
     
     
         5 . A composition according to  claim 4  further comprising an excipient. 
     
     
         6 . A method of preventing or treating a psychological disorder comprising the step of:
 administering to a subject in need thereof a therapeutically effective amount of a DMT analogue compound according to  claim 1 .   
     
     
         7 . A method of preventing or treating a psychological disorder comprising the step of:
 administering to a subject in need thereof a composition according to  claim 2 .   
     
     
         8 . A method of preventing or treating inflammation and/or pain comprising the step of:
 administering to a subject in need thereof a therapeutically effective amount of a DMT analogue compound according to  claim 1 .   
     
     
         9 . A method of preventing or treating inflammation and/or pain comprising the step of:
 administering to a subject in need thereof a composition according to  claim 2 .   
     
     
         10 . A method of modulating activity of a mitogen activating protein, neurogenesis, and/or neurite outgrowth comprising the step of:
 administering to a subject in need thereof a therapeutically effective amount of a DMT analogue compound according to  claim 1 .   
     
     
         11 . A method of modulating activity of a mitogen activating protein, neurogenesis, and/or neurite outgrowth comprising the step of:
 administering to a subject in need thereof a composition according to  claim 2 .   
     
     
         12 . The composition of  claim 2  wherein the DMT analogue compound is crystalline EPT hydrofumarate. 
     
     
         13 . The composition of  claim 2  wherein the DMT analogue compound is MALT hydrofumarate. 
     
     
         14 . The composition of  claim 2  wherein the DMT analogue compound is crystalline MALT hydrofumarate. 
     
     
         15 . The composition of  claim 2  wherein the DMT analogue compound is DBT iodide. 
     
     
         16 . The composition of  claim 2  wherein the DMT analogue compound is crystalline DBT iodide. 
     
     
         17 . A composition of  claim 2  wherein the DMT analogue compound is crystalline DiPT hydrofumarate. 
     
     
         18 . The DMT analogue compound of  claim 1 , wherein the DMT analogue compound is N-methyl-N-allyl-tryptamine (MALT) hydrofumarate. 
     
     
         19 . The DMT analogue compound of  claim 1 , wherein the DMT analogue compound is N—N-dibutyl-tryptamine (DBT) iodide. 
     
     
         20 . A composition comprising a DMT analogue compound according to  claim 2  and a second component selected from (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) one or two purified cannabinoids, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a purified erinacine, and (h) a purified hericenone.